Sign in
CATX Stock Price, Chart, Stats & News
Perspective Therapeutics, Inc.
Save
Perspective Therapeutics, Inc. (CATX) does not currently pay a dividend.
–
Market cap
–
Current P/E
25.71x
Forward P/E
CATX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -166.35% |
Operating margin | 1086.33% |
Pretax margin | -12356.00% |
Net margin | -12261.71% |
Effective tax rate | 0.76% |
ROA | -38.63% |
ROE | -41.27% |
D/E | 0.01x |
Interest coverage ratio | 36.84x |
CATX valuation
P/E | – |
P/S | 356.51x |
P/B | 1.45x |
P/CF | -4.39x |
P/FCF | -3.93x |
P/OCF | -4.39x |
PEG | -0.71x |
EV multiple | -5.30x |
About
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Similar securities
Based on sector and market capitalization
Report issue